Rapid Assessment of Drug Abuse: Smart City Tools (R41/R42 - Clinical Trial Optional) | RFA DA 20 020

Opportunity Information: Apply for RFA DA 20 020

Rapid Assessment of Drug Abuse: Smart City Tools (R41/R42 - Clinical Trial Optional), funding opportunity number RFA-DA-20-020, is a National Institutes of Health (NIH) small business grant opportunity designed to push forward practical, commercially viable technologies that strengthen how communities use wastewater testing to monitor illicit drug use in near real time. The central idea is to treat wastewater monitoring as a smart-city public health tool: instead of relying only on traditional indicators like surveys, overdose reports, or law enforcement data (which can be delayed or incomplete), applicants are encouraged to develop methods and systems that can measure drug signals in wastewater and translate those measurements into timely, actionable intelligence about changing drug patterns.

The opportunity is structured under the SBIR Phased Innovation mechanism, using the R41/R42 activity codes. In general terms, Phase I (R41) supports early feasibility and proof-of-concept work, while Phase II (R42) supports further development, validation, and steps toward commercialization. The “Clinical Trial Optional” label signals that a clinical trial is not required for eligibility, but certain kinds of human-subjects or clinical-trial-like components could be proposed if they legitimately fit the research plan and meet NIH requirements. That said, most wastewater-based epidemiology projects focus on environmental sampling and analytics rather than clinical interventions, so applicants would typically emphasize technology development, validation, and implementation in real-world municipal contexts.

From a technology standpoint, NIH is looking for innovations that improve the utilization of wastewater testing for dynamic monitoring of illicit drugs. That can include better sampling approaches (for example, methods that increase representativeness over time or across neighborhoods), improved analytical chemistry and detection workflows (such as more sensitive, specific, faster, or cheaper assays for drug metabolites), data processing and interpretation platforms (including software that converts lab measurements into estimates and trends), and integrated systems that connect sampling, lab analysis, and reporting in a way that supports rapid public health decision-making. The emphasis on “smart city tools” suggests a strong interest in solutions that can be deployed at scale, operate continuously or frequently, and produce outputs that local officials can interpret and use quickly, such as dashboards, automated alerts, or decision-support systems. Because the announcement highlights commercialization potential, applicants are expected to articulate a credible path to market, including who the customers are (for example, municipal utilities, public health departments, state agencies, or service providers), what the adoption barriers are, and how the product would be sustained beyond the grant.

Eligibility is limited to small businesses, consistent with the SBIR program’s intent to stimulate technological innovation in the private sector. The notice also makes clear that non-U.S. (foreign) institutions are not eligible to apply, and non-U.S. components of U.S. organizations are not eligible to apply. However, foreign components as defined in the NIH Grants Policy Statement may be allowed, meaning a U.S.-based applicant might be able to include certain foreign collaborations or activities if they meet NIH’s definition and are appropriately justified, but the applying organization itself must be a qualifying U.S. small business and the main project structure must remain compliant with NIH policy.

Administratively, this is a discretionary grant opportunity from NIH, aligned with the health mission area and identified under CFDA number 93.279 (drug abuse and related research). The opportunity’s original closing date was 2019-08-07, with a creation date of 2019-05-15, indicating it was posted for a specific funding cycle. While the provided data do not list an award ceiling or expected number of awards, the SBIR format typically involves milestone-based progress from feasibility to development, and applicants would be expected to budget and plan accordingly across phases, including clear technical milestones, validation plans, and deliverables that support eventual commercialization.

In practical terms, a strong proposal under this announcement would read like a product-focused R and D plan: it would identify a concrete problem with current wastewater drug monitoring (for example, slow turnaround times, inconsistent sampling, limited detection of emerging synthetic drugs, difficulty translating measurements into neighborhood-level signals, high operational cost, or lack of standardized reporting), propose a technology that measurably improves performance, and show how it could be adopted by real municipal stakeholders. The overall goal is to help communities detect and respond to shifts in illicit drug use faster and more accurately, using wastewater as a scalable, population-level signal that can complement other public health and public safety data sources.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Rapid Assessment of Drug Abuse: Smart City Tools (R41/R42 - Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279.
• This funding opportunity was created on 2019-05-15.
• Applicants must submit their applications by 2019-08-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: Small businesses.

Apply for RFA DA 20 020

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: